Abstract: Methods and compositions for preventing or reducing weight gain and associated metabolic syndrome in patients receiving atypical antipsychotic drugs for treatment of mental illnesses are described. The invention comprises administering to a patient in need of treatment an effective amount of a dopamine agonist in conjunction with an effective amount of an atypical antipsyochotic drug. In one embodiment of the invention, the dopamine agonist is pramipexole. The dopamine agonist may be administered in a low dose, such as less than 1 mg per day of pramipexole. Examples of atypical antipsychotic drugs which may be administered in conjunction with the dopamine agonist include clozapine, olanzapine, quetiapine and risperadone.
Abstract: The invention relates to salts of 1-alkylamino-1-deoxypolyols and 9-oxoacridine-10-acetic acid of the general formula (I): wherein A+ is (II) wherein R is selected from the group consisting of ethyl, propyl, butyl, medicinal preparations comprising as an active ingredient salts of formula (I) and/or a mixture of said salt of formula (I) or 9-oxoacridine-10-acetic acid of the formula: and one or more 1-alkylamino-1-deoxypolyols of the general formula (II): wherein: R is selected from the group consisting of ethyl, propyl, butyl.
Abstract: Although it can be farnesylated, the mutant lamin A protein expressed in Hutchison Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression.
Type:
Grant
Filed:
July 25, 2007
Date of Patent:
November 23, 2010
Assignees:
The United States of America as represented by the Department of Health and Human Services, The Regents of the University of Michiga, Progeria Research Foundation, Inc., The University of North Carolina at Chapel Hill
Inventors:
Leslie B. Gordon, Francis S. Collins, Thomas Glover, Michael W. Glynn, Brian C. Capell, Adrienne D. Cox, Channing J. Der
Abstract: [Problems] To provide a compound which is useful as an NMDA receptor antagonist. [Means for Solution] The present inventors have studied a compound having an NMDA receptor antagonistic action, and confirmed that the fused indane compound of the present invention has an excellent NMDA receptor antagonistic action, thereby completed the present invention. The fused indane compound of the present invention has an excellent NMDA receptor antagonistic action and can be used as a prophylactic and/or therapeutic agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, intractable depression, attention deficit hyperactivity disorder, migraines, or the like.
Abstract: The present disclosure relates to pyridoindolone derivatives of general formula (I): in which R1 to R5 are as defined in the specification, to processes for preparing said derivatives, and to methods of use thereof.
Type:
Grant
Filed:
October 16, 2008
Date of Patent:
October 19, 2010
Assignee:
sanofi-aventis
Inventors:
Bernard Bourrie, Pierre Casellas, Jean-Marie Derocq, Samir Jegham, Yvette Muneaux
Abstract: The present invention provides for a storage stable pharmaceutical liquid suspension for oral administration having a pharmaceutically effective amount of an antihistamine. The storage stable suspension preferably contains loratadine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid suspension as well as a method of treating a mammal with a therapeutically effective amount of loratadine in the stable pharmaceutical liquid suspension.
Abstract: Compounds of formula: and pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2, R3, R4, and R5, have the meanings given in the description; pharmaceutical compositions comprising said compounds; and processes for preparing said compounds and methods of use thereof.
Type:
Grant
Filed:
October 18, 2006
Date of Patent:
October 12, 2010
Assignee:
sanofi-aventis
Inventors:
Bernard Bourrie, Pierre Casellas, Paola Ciapetti, Jean-Marie Deroco, Samir Jegham, Yvette Muneaux, Camille-Georges Wermuth
Abstract: The present invention relates to substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Type:
Application
Filed:
December 30, 2009
Publication date:
September 23, 2010
Applicant:
ArQule, Inc.
Inventors:
Syed M. Ali, Mark A. Ashwell, Sudharshan Eathiraj, Eugene Kelleher, Jean-Marc Lapierre, Yanbin Liu, Nivedita Namdev, Rocio Palma, Manish Tandon, David Vensel, Neil Westlund, Hui Wu, Rui-Yang Yang
Abstract: The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.
Abstract: The invention relates to the use of Loratadine 10 mg prior to flying to prevent upper respiratory inflammation and sinus infections caused from exposure to bacteria and viruses while flying. People are packed together in airplanes, which has dry and polluted air. Flying is one of the more common places to pick up cold viruses and airborne bacteria. Use of Loratadine 10 mg before the plane takes off to shrink the nasal lining helps prevent susceptibility to bacteria and viruses.
Abstract: The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Type:
Application
Filed:
February 17, 2010
Publication date:
September 9, 2010
Inventors:
Yat Sun Or, Xiaowen Peng, Ce Wang, Lu Ying, Datong Tang, Yao-Ling Qiu
Abstract: The present invention relates to imidazo[1,2-a]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Type:
Grant
Filed:
October 18, 2006
Date of Patent:
September 7, 2010
Assignee:
Merck & Co., Inc. and Merck Sharp & Dohme Corp.
Abstract: The invention provides a class of dopamine transporter inhibitors of formula (I) (DAT inhibitors), packaged pharmaceuticals comprising such inhibitors, and their uses in treating, or manufacturing medicaments for treating disease conditions including Parkinson's disease, when assessed by one or more of Hoehn and Yahr Staging of Parkinson's Disease, Unified Parkinson Disease Rating Scale (UPDRS), and Schwab and England Activities of Daily Living Scale. Related business methods such as marketing the inhibitors to healthcare providers are also provided.
Type:
Application
Filed:
February 21, 2006
Publication date:
August 26, 2010
Applicant:
Prexa Pharmaceuticals, Inc. c/o Advent Healthcare Ventures
Abstract: Certain 4-aryl-piperidine compounds, including N-substituted 9?-substituted-5-(3-substituted-phenyl)morphans and N-substituted octahydro-4a-(3-hydroxyphenyl)-10a-methyl-benzo[g]isoquinolines, pharmaceutical compositions, and methods of their use, inter alia, as opioid antagonists are disclosed.
Type:
Grant
Filed:
May 25, 2006
Date of Patent:
August 3, 2010
Assignee:
Adolor Corporation
Inventors:
Roland Ellwood Dolle, Bertrand Le Bourdonnec
Abstract: The present invention provides for a storage stable pharmaceutical liquid suspension for oral administration having a pharmaceutically effective amount of an antihistamine. The storage stable suspension preferably contains loratadine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid suspension as well as a method of treating a mammal with a therapeutically effective amount of loratadine in the stable pharmaceutical liquid suspension.
Abstract: This invention provides novel arylindenopyridines and arylindenopyrimidines of the formula: wherein R1, R2, R3, R4, and X are as defined above, and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A2a receptors. This invention also provides therapeutic and prophylactic methods using the instant compounds and pharmaceutical compositions.
Type:
Grant
Filed:
October 23, 2008
Date of Patent:
July 20, 2010
Assignee:
Janssen Pharmaceutica, N.V.
Inventors:
Geoffrey R. Heintzelman, James Lawrence Bullington, Kenneth C. Rupert
Abstract: [Problem] To provide a compound which can be used in the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly in the treatment of irritable bowel syndrome (IBS) and/or prevention of migraine. [Means for Resolution] It was found that an acylguanidine derivative having a tricyclic structure or a pharmaceutically acceptable salt thereof has a strong antagonism to 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of the present invention having antagonism to both of the receptors showed superior pharmacological action in comparison with the case of the single use of an antagonist selective for either one of the receptors. Based on the above, the compound of the present invention is useful in preventing and/or treating diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly in treating irritable bowel syndrome (IBS) and/or preventing migraine.
Abstract: Methods of treating and/or preventing a cardiovascular disease in a human suffering from an allergic and/or inflammatory condition or cardiovascular disease by administrating an effective amount of loratadine, in combination with an effective amount of montelukast, for such treating and/or preventing are disclosed.
Abstract: The present invention relates to a tablet comprising at least a first and second active, the first active being in the form of a non-aqueous granulate, the second active ingredient being in the form of melt extrudated granules or a granulate (aqueous or non-aqueous). The first and second active forms are blended together. The present invention is further directed to a method of producing said tablet.
Abstract: The present invention provides for tricyclic compounds having the formula (I), wherein R1, R2, R5, R6, R7, and R8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
Type:
Grant
Filed:
May 8, 2006
Date of Patent:
June 15, 2010
Assignee:
Bristol-Myers Squibb Company
Inventors:
William J. Pitts, James Kempson, Junqing Guo, Jagabandhu Das, Charles M. Langevine, Steven H. Spergel, Scott Hunter Watterson
Abstract: The present invention relates to amide and urea derivatives of heteroaryl-substituted diazatricycloalkanes, pharmaceutical compositions including the compounds, methods of preparing the compounds, and methods of treatment using the compounds. More specifically, the methods of treatment involve modulating the activity of the ?7 nAChR subtype by administering one or more of the compounds to treat or prevent disorders mediated by the ?7 nAChR subtype. The diazatricycloalkanes typically consist of a 1-azabicyclooctane fused to pyrrolidine ring. The substitutent heteroaryl groups are 5- or 6-membered ring heteroaromatics, such as 3-pyridinyl and 5-pyrimidinyl moieties, which are attached directly to the diazatricycloalkane. The secondary nitrogen of the pyrrolidine moiety is substituted with an arylcarbonyl (amide type derivative) or an arylaminocarbonyl (N-arylcarbamoyl) (urea type derivative) group.
Type:
Grant
Filed:
August 21, 2006
Date of Patent:
June 8, 2010
Inventors:
Anatoly Mazurov, Lan Miao, Jozef Klucik
Abstract: Stabilized desloratadine-containing pharmaceutical compositions are prepared using complexes formed by combining desloratadine and a resin in the acidic form.
Abstract: The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
Abstract: The present invention relates to compounds of formula (I) wherein R1 is as defined in the description, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
Type:
Grant
Filed:
June 17, 2004
Date of Patent:
May 18, 2010
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Markus Boehringer, Bernd Kuhn, Thomas Luebbers, Patrizio Mattei, Robert Narquizian, Hans Peter Wessel
Abstract: The present invention is directed to novel substituted fused aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
Type:
Grant
Filed:
November 22, 2005
Date of Patent:
May 18, 2010
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Scott D. Edmondson, Anthony Mastracchio, Jason M. Cox
Abstract: The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to the diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides intermediates and processes for preparing these compounds.
Type:
Grant
Filed:
October 13, 2006
Date of Patent:
May 11, 2010
Inventors:
Robert L. Dow, Kevin K. Liu, Bradley P. Morgan, Andrew G. Swick
Abstract: The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds.
Type:
Grant
Filed:
March 7, 2005
Date of Patent:
May 11, 2010
Assignee:
Actelion Pharmaceuticals, Ltd.
Inventors:
Anja Fecher, Heinz Fretz, Kurt Hilpert, Markus Riederer
Abstract: Apparatus and methods deliver treatment agents simultaneously with capnic gases. The capnic gases can enhance the effectiveness of the treatment agent for treating rhinitis, lower the dosage of drug or concentration of agent necessary to achieve a therapeutic result, or both. Exemplary capnic gases include carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases.
Type:
Application
Filed:
December 30, 2009
Publication date:
April 29, 2010
Applicant:
CAPNIA, INC.
Inventors:
Julia S. Rasor, Ned S. Rasor, Gerard F. Pereira
Abstract: Disclosed are methods of treating taxane sensitive tumors (i.e., cancers treatable with taxanes) using a taxane and the discontinuous dosing of lonafarnib.
Type:
Application
Filed:
October 23, 2007
Publication date:
April 29, 2010
Inventors:
Susan Arbuck, Paul Kirschmeier, Brian Long, Genevieve A. Menard, Siu-Long Yao
Abstract: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film.
Type:
Application
Filed:
November 9, 2009
Publication date:
April 15, 2010
Applicant:
MonoSol RX, LLC
Inventors:
Robert K. Yang, Richard C. Fuisz, Garry L. Myers, Joseph M. Fuisz
Abstract: This invention provides estrogen receptor modulators having the structure: wherein R1 to R7 are as defined in the specification; or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
December 20, 2005
Date of Patent:
April 13, 2010
Assignee:
Wyeth LLC
Inventors:
Richard Dale Coghlan, William Floyd Fobare, Eugene John Trybulski
Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.
Type:
Grant
Filed:
April 25, 2005
Date of Patent:
April 6, 2010
Assignee:
Pfizer, Inc.
Inventors:
Klaus Ruprecht Dress, Qiyue Hu, Ted William Johnson, Michael Bruno Plewe, Steven Paul Tanis, Huichun Zhu, Junhu Zhang
Abstract: Pharmaceutical compositions comprising phenylephrine in a sustained release oral dosage formulation. Compositions can comprise phenylephrine alone or phenylephrine in combination additional pharmaceutically active substances such as an antihistamine and/or an analgesic.
Abstract: The present invention relates to a method for treating a behavior disorder comprising the administration of a therapeutically effective amount of antihistamine, such as cetirizine, fexofenadine; loratadine, and desloratadine. The behavioral disorders may include ADHD, anxiety, depression, and autism. The method may include the administration of the antihistamine in combination with a stimulant medication, such as methylphenidate, thereby to achieve a synergistic effect. In any event, the amount of antihistamine and/or stimulant is effective to downregulate neurotrophic factors such as nerve growth factor or CD40. The invention is also directed to a method of preventing the onset of behavior disorders in patients presenting with symptoms of allergic rhinitis.
Abstract: The present invention provides substantially pure desloratadine having an HPLC purity greater than 99.5% and having an absorbance less than 0.15 Au at 420 nm for a 5% w/v solution in methanol, which does not show a peak for an impurity at a relative retention time in the range from about 0.85 to about 0.99 (relative to desloratadine appearing at a retention time of 25±5 minutes), which is greater than the discard limit set at less than 0.025% of the total area, when tested according to an HPLC method performed using a Hypersil BDS C8 column (15 cm×4.6 mm, 5 ?m particle size) with the following parameters: Mobile phase: Buffer solution having a pH of about 3, methanol and acetonitrile in a volume ratio of 8:1:1. Injection volume: 20 ?l Flow rate: 1.5 ml/minute Run time: 75 minutes. Discard limit: Set at less than 0.
Abstract: The problem of the present invention is to provide a compound having a GR selective binding activity, which shows less action on other nuclear receptors such as progesterone receptor (PR), mineralocorticoid receptor (MR) and the like. The present invention provides a condensed tetrahydroquinoline compound represented by the following formula (I) wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof or a hydrate thereof.
Abstract: Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.
Abstract: Dry syrup preparations comprising loratadine as a hydrophobic medicinal drug are provided. The loratadine dry syrup preparations can be produced using a cellulose material or an argininic acid salt together with sugar.
Abstract: A galenical form for the administration transmucously of at least one active ingredient, characterized in that the active ingredient is in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 20% by mass of alcohol so as to allow rapid absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. Uses of the galenical form are also disclosed.
Abstract: A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2% of desloratadine decomposition products is disclosed. A solid composition comprising an anti-allergic effective amount of desloratadine and at least one, and preferably two pharmaceutically acceptable antioxidants is also disclosed.
Abstract: An active pharmaceutical ingredient comprising 95% of form I of desloratadine and 5% of form II of desloratadine is disclosed. Also disclosed are a process for its preparation as well as a bioavailable and stable formulation containing this active pharmaceutical ingredient for the treatment of allergic diseases like allergic rhinitis, chronic idiopathic urticaria, asthma and other similar diseases. The compositions are formulated such as to provide protection to the drug from acidic excipients. The compositions of the present invention comprise desloratadine intimately mixed with hydrogenated vegetable oil and certain other excipients including acidic excipients.
Abstract: The present invention features an orally disintegrating dosage form including from about 5% to about 40%, by weight, of at least one hydrated salt and a pharmaceutically active agent, wherein the at least hydrated salt has a dehydration temperature of from about 20 to about 120° C.
Abstract: The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the System can be retained in the gastric region for a prolonged period of time. It comprises of a core (I), one or more layers (II, IV, V) coated over the core and a preformed hollow space (III). The invention also concerns with a process for preparation of the System and a method for treating/preventing diseases, by administering to a subject in need thereof, the System of the invention.
Abstract: Disclosed are compositions and methods for modulating protein trafficking and treating or preventing disorders characterized by impaired protein trafficking. Also disclosed are methods for identification of compounds that rescue protein trafficking defects and methods of enhancing protein production.
Abstract: This invention relates to an oramucosal pharmaceutical dosage form in the form of a wafer. The wafer comprises a porous, hydroscopic, muco-adhesive polymeric matrix with at least one desired pharmaceutically active compound added thereto. The polymer is selected from a number of polymers having different dissolution rates and, in use when taken orally, the matrix adheres to an oramucosal surface to dissolve over a predetermined period of time to release the pharmaceutically active compound. The invention also extends to a method of manufacturing an oramucosal pharmaceutical dosage form in the form of a wafer which involves freeze drying or lyophilisation.
Type:
Application
Filed:
September 19, 2006
Publication date:
December 24, 2009
Inventors:
Rupal Patel, Viness Pillay, Michael Danckwerts